June 2023 – ITHEMYC kicks off

Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC)

The Horizon Europe programme has funded the ITHEMYC project to establish a critical path for selection of promising innovative adjunct TB immunotherapies and progress 2 of these immunotherapies to completion of preclinical proof of concept.

Read more